Context Therapeutics Stock Analysis
| CNTX Stock | USD 0.82 0.07 7.87% |
Context Therapeutics is undervalued with Real Value of 2.06 and Target Price of 5.75. The main objective of Context Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Context Therapeutics is worth, separate from its market price. There are two main types of Context Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Context Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Context Therapeutics is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Context Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Context Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. Context Stock Analysis Notes
About 80.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.88. Some equities with similar Price to Book (P/B) outperform the market in the long run. Context Therapeutics recorded a loss per share of 0.28. The entity had not issued any dividends in recent years. Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Context Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. For more info on Context Therapeutics please contact the company at 267-225-7416 or go to https://www.contexttherapeutics.com.Context Therapeutics Investment Alerts
| Context Therapeutics had very high historical volatility over the last 90 days | |
| Context Therapeutics has some characteristics of a very speculative penny stock | |
| Context Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (26.73 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Context Therapeutics currently holds about 42.92 M in cash with (14.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Context Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 80.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Piper Sandler Remains a Buy on Context Therapeutics - The Globe and Mail |
Context Therapeutics Upcoming and Recent Events
Earnings reports are used by Context Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Context Largest EPS Surprises
Earnings surprises can significantly impact Context Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-20 | 2024-12-31 | -0.0567 | -0.03 | 0.0267 | 47 | ||
2024-08-07 | 2024-06-30 | -0.0667 | -0.04 | 0.0267 | 40 | ||
2023-05-10 | 2023-03-31 | -0.34 | -0.4 | -0.06 | 17 |
Context Stock Institutional Investors
| Shares | Alyeska Investment Group, L.p. | 2025-03-31 | 1.7 M | Woodline Partners Lp | 2025-03-31 | 1.4 M | Sio Capital Management, Llc | 2025-03-31 | 1.3 M | Ally Bridge Group (ny) Llc | 2025-03-31 | 1.2 M | Allostery Investments Lp | 2025-03-31 | 950.2 K | Blackrock Inc | 2025-03-31 | 849 K | Affinity Asset Advisors, Llc | 2025-03-31 | 660.6 K | Geode Capital Management, Llc | 2025-03-31 | 639.2 K | Renaissance Technologies Corp | 2025-03-31 | 425.5 K | Mpm Oncology Impact Management Lp | 2025-03-31 | 14.7 M | Avidity Partners Management Lp | 2025-03-31 | 7.5 M |
Context Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 79.84 M.Context Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.29) | |
| Return On Capital Employed | (0.31) | (0.33) | |
| Return On Assets | (0.27) | (0.29) | |
| Return On Equity | (0.28) | (0.29) |
Management Efficiency
Context Therapeutics has return on total asset (ROA) of (0.3801) % which means that it has lost $0.3801 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5559) %, meaning that it created substantial loss on money invested by shareholders. Context Therapeutics' management efficiency ratios could be used to measure how well Context Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.29 in 2025. Return On Capital Employed is likely to drop to -0.33 in 2025. At this time, Context Therapeutics' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 58.3 M in 2025, whereas Other Assets are likely to drop 0.86 in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.63 | 2.38 | |
| Tangible Book Value Per Share | 1.63 | 2.38 | |
| Enterprise Value Over EBITDA | 1.23 | 1.29 | |
| Price Book Value Ratio | 0.64 | 0.68 | |
| Enterprise Value Multiple | 1.23 | 1.29 | |
| Price Fair Value | 0.64 | 0.68 | |
| Enterprise Value | -28.8 M | -27.4 M |
Understanding the operational decisions made by Context Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Technical Drivers
As of the 21st of July, Context Therapeutics shows the Downside Deviation of 4.08, risk adjusted performance of 0.0436, and Mean Deviation of 3.75. Context Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Context Therapeutics Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of Context Therapeutics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Context Therapeutics short-term fluctuations and highlight longer-term trends or cycles.
Context Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Context Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Context Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Context Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Context Therapeutics Outstanding Bonds
Context Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Context Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Context bonds can be classified according to their maturity, which is the date when Context Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Context Therapeutics Predictive Daily Indicators
Context Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Context Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Context Therapeutics Forecast Models
Context Therapeutics' time-series forecasting models are one of many Context Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Context Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Context Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Context Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Context shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Context Therapeutics. By using and applying Context Stock analysis, traders can create a robust methodology for identifying Context entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current Context Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Context analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Context analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 5.75 | Strong Buy | 5 | Odds |
Most Context analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Context stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Context Therapeutics, talking to its executives and customers, or listening to Context conference calls.
Context Stock Analysis Indicators
Context Therapeutics stock analysis indicators help investors evaluate how Context Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Context Therapeutics shares will generate the highest return on investment. By understating and applying Context Therapeutics stock analysis, traders can identify Context Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 14.4 M | |
| Common Stock Shares Outstanding | 58.4 M | |
| Total Stockholder Equity | 95.3 M | |
| Total Cashflows From Investing Activities | -14.8 M | |
| Property Plant And Equipment Net | 230.8 K | |
| Cash And Short Term Investments | 94.4 M | |
| Cash | 94.4 M | |
| Accounts Payable | 1.5 M | |
| Net Debt | -94.2 M | |
| 50 Day M A | 0.6749 | |
| Total Current Liabilities | 2.7 M | |
| Other Operating Expenses | 29.9 M | |
| Non Current Assets Total | 230.8 K | |
| Stock Based Compensation | 841.9 K |
Additional Tools for Context Stock Analysis
When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.